Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.
Our goal is to be a leading specialty company, recognized and trusted by patients and providers for our commitment to urology.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients with urological conditions that are overlooked, misunderstood or not well managed.
Careers at Urovant Sciences offer exceptional possibilities.
Urovant Sciences is Powered by People and Possibilities™. When you join us, you become part of a world-class team and dynamic culture dedicated to being the best in all that we do and driving the best possible outcomes every day.
Powered by people and possibilities
In The News

September 13, 2021
Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate
September 03, 2021
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association
August 18, 2021
Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the 2021 Annual Meeting of the American Urological Association